As at his report dated June 10, PLife REIT had renewed the master leases for its three Singapore hospitals for 20.4 years till December 2042.
SAC Capital analyst Lam Wang Kwan has started coverage on ParkwayLife REIT (PLife REIT) with a “hold” recommendation and a target price of $4.69.
To Lam, the REIT offers several positives including its income stability and built-in rental escalation. That said, his target price and recommendation are capped by a lack of near-term catalysts.
